|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.80 EUR | -2.63% |
|
+2.01% | +2.70% |
| 06-10 | Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT |
| 06-09 | Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 1,982 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 1.02% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,539 | 1,595 | 1,767 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 10.18% | 3.64% | 10.83% |
| P/E Ratio | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -7.97x | -9.46x | -13.1x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 3.71x | 3.99x | 3.95x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.6x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.42x | 3.33x | 2.62x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.43x | 2.68x | 2.34x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -6.33x | -9.97x | -26.5x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -5.95x | -9.18x | -20.6x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -8.75x | -13.8x | -25.2x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -11.4% | -7.26% | -3.97% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.215 | -1.865 | -1.347 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 448.7 | 595.6 | 755.9 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -243 | -159.9 | -66.57 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -258.7 | -173.7 | -85.83 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -240.9 | -156.5 | -125.8 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -443.1 | -387.2 | -214.4 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 17.64 | 17.64 | 17.64 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,355 | - | - |
| Announcement Date | 3/1/22 | 3/1/23 | 2/27/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.83x | 3.42x | 9.23x | 0.64% | 62.21B | |
| 29.23x | 5.92x | 17.17x | 0.54% | 59.45B | |
| 31.79x | 10.74x | 20.27x | -.--% | 38.9B | |
| -48.35x | 2.94x | 8.68x | 3.8% | 36.4B | |
| 32.29x | 3.5x | 10.56x | -.--% | 29.52B | |
| 17.45x | 2.94x | 9.1x | -.--% | 21.54B | |
| -5.74x | 7.71x | -4.71x | -.--% | 19.7B | |
| 46.9x | 4.95x | 35.54x | -.--% | 16.18B | |
| 24.54x | 5.08x | 13.7x | -.--% | 15.89B | |
| Average | 15.99x | 5.25x | 13.28x | 0.55% | 33.31B | |
| Weighted average by Cap. | 15.22x | 5.23x | 13.03x | 0.7% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
